Musk's brain-computer interface company is about to conduct its first human clinical trial
Elon Musk's brain-machine interface company, Neuralink, is poised to embark on its first-ever human clinical trials, marking another significant milestone since receiving FDA clinical approval in May of this year.
Neuralink has announced that it has obtained approval from an independent review committee and is initiating recruitment for human trials involving brain-machine interfaces (BCIs) implanted in the brains of paralyzed patients. Notably, this research will utilize surgical robots to implant devices in the brain regions responsible for controlling human movement.
According to Musk's description, Neuralink's devices can convert brain signals into actions, with an initial focus on two applications: restoring human vision and assisting individuals who cannot move their muscles in controlling devices such as smartphones, and potentially even restoring full-body function for spinal cord injury patients.
Neuralink states that this human trial will span six years, with participants initially joining an 18-month study, followed by at least two hours of brain-machine interface research per week. The goal of the study is to test the safety and effectiveness of Neuralink's wireless fully implanted brain-machine interface, enabling paralyzed patients to control external devices using their brains.
Currently, the company has started recruiting patients for clinical trials, with individuals suffering from cervical spinal cord injuries or amyotrophic lateral sclerosis (ALS) potentially meeting the criteria for participation in this trial.
More Application-Related Electronic Components
MC79M05CDTRKG
Linear regulators with negative feedback designed to provide a constant 5V output at a maximum current of 500mA
KSZ8895MQXIA
High-speed networking switch
XGL4030-222MEC
2.2uH ±20% 7A 1616 Power Inductors ROHS
0900LP15B0063E
Ceramic Filters Low Pass 900MHz 0.9dB 50Ohm SMD 8Pin T/R
ZXMN10B08E6TA
ZXMN10B08E6TA is a N Channel MOSFET, featuring a voltage rating of 100V and a maximum current of 1.6A, with a low on-resistance of 230mΩ at 10V
ZXMN6A07FTA
Small Signal Field-Effect Transistor
MLX90614ESF-DCI-000-TU
Digital Temperature Sensor MLX90614ESF-DCI-000-TU, Operating Range: -40°C to 85°C, TO39 Enclosure
ZVN2106A
channel MOSFET with a voltage rating of 60V, current rating of 0.45A, and power dissipation of 0.7W, packaged in TO92
READ ALSO
-
Compatible with ADS1258, 16-channel 24-bit SC1642 is used in medical biochemical detection systems Date: 26/09/2023
A biochemical analyzer is a system that employs various electrochemical and optical techniques to analyze and detect biological samples. This system comprises an optical engine, sample movement/flow control, automated control and processing, power management, and environmental monitoring and control (temperature, pressure, humidity). To enhance efficiency, biochemical analyzers available in the market are highly automated.
-
Rockley Photonics completes trial of wearable blood pressure monitoring device Date: 26/09/2023
Recently, Rockley Photonics, a developer of silicon photonics technology for healthcare applications, announced the results of trials using their wearable device to monitor blood pressure. These trials, approved by an Institutional Review Board (IRB), build upon preliminary pilot studies completed in 2022, marking progress in the commercialization of Rockley Photonics' first-generation Alpha device.
-
Application of ATA-4315 high-voltage power amplifier in high-frequency physical therapy instrument drive Date: 26/09/2023
In modern society, with the pressures of life and work, coupled with unhealthy lifestyle habits, our bodies may inevitably encounter various health issues. As technology advances, we are witnessing the increasing application of multiple instruments and devices in clinical settings to assist medical professionals in treatment. One such device is the high-frequency physiotherapy machine.